473 6. Complicanze tardive Bibliografia [1] Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW, Pereira SE, Nash RA, Mielacarek M, Fero ML, Warren WH, Sanders JE, Storb RF, Appelbaum FR, Storer BE, Martin PJ. Comparative analysis of risk factors for acute graft-versushost disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117(11):3214–3219 [2] Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR et al. Graft-vs-Host Disease Working Committee of the CIBMTR. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015;21(2):266-74. doi: 10.1016/j.bbmt.2014.10.021. Epub 2014 Oct 30 [3] Sarantopoulos S., Ritz J. Aberrant B-cell homeostasis in chronic GVHD. Blood. 2015; 125 (11):1703-1707. doi: 10.1182/blood-2014-12-567834 [4] Svegliati S, Olivieri A, Campelli N, Luchetti M, Poloni A, Trappolini S, et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood. 2007;110 (1):237-41. doi: 10.1182/blood-2007-01-071043. Epub 2007 Mar 15. [5] Cooke KR, Luznik L, Sarantopoulos S, Hakim FT, Jagasia M, Fowler DH, et al. The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017; 23(2):211-234. [6] Zeiser R, Blazar RB Pathophysiology of Chronic Graftversus-Host Disease and Therapeutic Targets. Engl J Med. 2017;377(26):2565-2579. doi: 10.1056/NEJMra1703472. [7] Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, et al; EBMT (European Society for Blood and Marrow Transplantation) Transplant Complications Working Party and the “EBMT−NIH (National Institutes of Health)−CIBMTR (Center for International Blood and Marrow Transplant Research) GvHD Task Force”. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant. 2018; 53(11):1401-141 [8] Moon JH, Sohn SK, Lambie A, Ellis L, Hamad N, Uhm J, et al. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival. Biol Blood Marrow Transplant. 2014; 20(4):556-63. doi: 10.1016/j.bbmt.2014.01.010. Epub 2014 Jan 18. [9] Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015; 21(3):389-401.e1. doi: 10.1016/j. bbmt.2014.12.001. Epub 2014 Dec 18. [10] Inamoto Y, Valdés-Sanz N, Ogawa Y, Alves M, Berchicci L, Galvin J et al. Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019; 25(2):e46-e54. doi: 10.1016/j.bbmt.2018.11.021. Epub 2018 Nov 24. [11] Treister N, Duncan C, Cutler C, Lehmann L. How we treat oral chronic graft-versus-host disease. Blood. 2012; 20(17):3407-18. doi: 10.1182/blood-2012-05-393389. Epub 2012 Aug 16. [12] Fall-Dickson JM, Pavletic SZ, Mays JW, Schubert MM. Oral Complications of Chronic Graft-Versus-Host Disease. J Natl Cancer Inst Monogr. 2019; 2019(53):lgz007. doi: 10.1093/jncimonographs/lgz007. [13] Matsukuma KE, Wei D, Sun K, Ramsamooj R, Chen M.J Diagnosis and differential diagnosis of hepatic graft versus host disease (GVHD). Gastrointest Oncol. 2016; 7(Suppl 1):S21-31. doi: 10.3978/j.issn.2078-6891.2015.036 [14] Hamilton BK, Goje O, Savani BN, Majhail NS, Stratton P. Clinical management of genital chronic GvHD. Bone Marrow Transplant. 2017; 52(6):803-810. doi: 10.1038/bmt.2016.315. [15] Chien JW, Duncan S, Williams KM, Pavletic SZ. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease..Biol Blood Marrow Transplant. 2010; 16(1 Suppl):S106-14 [16] Hakim A, Cooke KR, Pavletic SZ, Khalid M, Williams KM, Hashmi SK. Diagnosis and treatment of bronchiolitis obliterans syndrome accessible universally. Bone Marrow Transplant. 2019; 54(3):383-392. doi: 10.1038/s41409-018-0266-6. Epub 2018 Jul 23. [17] Bos S, Beeckmans H, Vanstapel A, Sacreas A, Geudens V, Willems L, Schreurs I, Vanaudenaerde BM, Schoemans H, Vos R. Pulmonary graft-versus-host disease and chronic lung allograft dysfunction: two sides of the same coin? Lancet Respir Med 2022; 10(8):796-810. doi: 10.1016/S2213-2600(22)00001-7 [18] Smith SR, Haig AJ, Couriel DR. Musculoskeletal, Neurologic, and Cardiopulmonary Aspects of Physical Rehabilitation in Patients with Chronic Graft-versus-Host Disease. Blood Marrow Transplant.2015; 21(5):799-808.doi: 10.1016/j.bbmt.2014.10.019. Epub 2014 Oct 23. [19] Lee SJ, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M, et al. Measuring therapeutic response in chronic graft-versushost disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant. 2015;21(6):984-999. 25. doi: 10.1016/j. bbmt.2015.02.025 [20] Palmer J, Chai X, Pidala J, Inamoto Y, Martin PJ, Storer B, et al. Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease. Blood. 2016; 127(1):160-6. doi: 10.1182/blood-2015-08-662874 [21] Martin PJ, Storer BE, Inamoto Y, Flowers MED, Carpenter PA, Pidala J, et al. An endpoint associated with clinical benefit after initial treatment of chronic graft-versushost disease. Blood. 2017;130(3):360-367 [22] Flowers ME, Apperley JF, van Besien K, Elmaagacli A, Grigg A, Reddy V, et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood. 2008;112(7):2667-2674. [23] Olivieri A, Cimminiello M, Corradini P, Mordini N, Fedele R, Selleri C, et al. Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. Blood. 2013; 122(25):4111-8. doi: 10.1182/blood-2013-05-494278 [24] Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, et al. Ruxolitinib in corticosteroid-refractory graftversus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015; 29(10):2062-8. doi: 10.1038/ leu.2015.212. [25] Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, et al REACH3 Investigators. Ruxolitinib for Glucocorticoid-RefractoryChronic Graft-versus-Host Disease. N Engl J Med. 2021; 385(3):228-238. doi: 10.1056/NEJMoa2033122. [26] Cutler C, Lee SJ, Arai S, Rotta M, Zoghi B, Lazaryan A, et al. on behalf of the ROCKstar Study Investigators. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood. 2021; 138(22):2278-2289. doi: 10.1182/blood.2021012021. [27] Kitko CL, Pidala J, Schoemans HM, Lawitschka A, Flowers ME, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report.Transplant Cell Ther. 2021; 27(7):545-557. doi: 10.1016/j.jtct.2021.03.033. [28] Ljungman P. Infectious complications and vaccines. Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):587-591. doi: 10.1182/hematology.2021000294.
RkJQdWJsaXNoZXIy ODUzNzk5